Mei Wang

Yangzhou, CN 
Yangzhou, CN 

Overview

Mei Wang practices practicing medicine in Yangzhou, China.

Her clinical expertise encompasses Colitis, Viral Gastroenteritis, Acute Pancreatitis, and Hemorrhagic Proctocolitis.

She is actively involved in clinical research, co-authoring 12 peer reviewed articles and participating in 2 clinical trials.

Gender

Female

Locations

Yangzhou, 225000, China
Other Locations
Yangzhou, China
Ganzhou, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
A Phase 3, Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Patients With Crohn's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 11, 2026
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
View 1 Less Clinical Trial

12 Total Publications

Oral liposomal co-delivery of ultrasmall ceria and 5-aminosalicylic acid alleviates DSS colitis via ROS scavenging and microbiome remodeling.
Oral liposomal co-delivery of ultrasmall ceria and 5-aminosalicylic acid alleviates DSS colitis via ROS scavenging and microbiome remodeling.
Journal: Journal of materials chemistry. B
Published: April 08, 2026

Frequently Asked Questions about Mei Wang

Is Mei Wang a top-rated expert for Colitis?

MediFind is an objective health platform that identifies experts based on real-world data. Mei Wang is classified as an Experienced expert for Colitis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Mei Wang participate in research or clinical trials?

Yes. Mei Wang has published 12 articles and abstracts on conditions like Colitis. You can view a list of Mei Wang's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Wang's expertise for a condition
ConditionClose
        View All 7 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile